Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer

The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer (NSCLC). In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuliang, Yang, Hongji, Ge, Xingping, Su, Lingfei, Zhang, Aifeng, Liang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104210/
https://www.ncbi.nlm.nih.gov/pubmed/27895753
http://dx.doi.org/10.3892/ol.2016.5171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104210/
https://www.ncbi.nlm.nih.gov/pubmed/27895753
http://dx.doi.org/10.3892/ol.2016.5171

Ejemplares similares